版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
NCCNClinicalPracticeGuidelinesinOncologyNCCNGuidelines®)AmpullaryAdenocarcinomarsionMarchVersion1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadex*MargaretA.Tempero,MD/Chair†‡UCSFHelenDillerFamilyComprehensiveCancerCenternternter**StephenW.Behrman,MD/Co-Lead¶TheUniversityofTennesseeeCenter**E.GabrielaChiorean,MD/Co-Lead†FredHutchinsonCancerResearchCenter/SeattleCancerCareAllianceyofMichiganRogelyofMichiganRogelCancerCenter**AlB.BensonIII,MD†RobertH.LurieComprehensiveCancerCenterofNorthwesternUniversityngramCancerCenterVincentChung,MDngramCancerCenterVincentChung,MD†yofHopeNationalMedicalCenter**BrianCzito,MD§DukeCancerInstituteofColoradoCancerCenterChiaroofColoradoCancerCenterMaryDillhoff,MD,MS¶TheOhioStateUniversityComprehensiveCancerCenter-JamesCancerHospitalandSoloveResearchInstituteTimothyR.Donahue,MD¶UCLAJonssonComprehensiveCancerCenterEfratDotan,MD†FoxChaseCancerCenterCristinaR.Ferrone,MD¶MassachusettsGeneralHospitalCancerCenteresPanelDisclosuresChristosFountzilas,MD‡RoswellParkComprehensiveCancerCenterJeffreyHardacre,MD¶CaseComprehensiveCancerCenter/UniversityHospitalsSeidmanCancerCenterandClevelandClinicTaussigCancerInstitutemanCancerCenteratBarnesmanCancerCenteratBarnesJewishHospitaltonUniversitySchoolofMedicineEdwardJ.Kim,MD,PhD†UCDavisComprehensiveCancerCenterfettCancerfettCancerCenterAndrewH.Ko,MD†UCSFHelenDillerFamilyComprehensiveCancerCenternterSmilowCancerHospitalnterSmilowCancerHospital**NoelleLoConte,MD†UniversityofWisconsinCarboneCancerCenter**AndrewM.Lowy,MD¶UCSanDiegoMooresCancerCenterMoravekPancreaticCancerActionNetworkPatricioM.Polanco,MD¶UTSouthwesternSimmonsComprehensiveCancerCenterONealComprehensiveCancerCenterONealComprehensiveCancerCenteratUABMarshaReyngold,MD,PhD§MemorialSloanKetteringCancerCenterrInstituteattherInstituteatthefUtah**JeanneShen,MD≠StanfordCancerInstituteMarkJ.Truty,MD,MS¶MayoClinicCancerCenterAbramsonCancerCenterattheAbramsonCancerCenteratthensylvaniaandWomensnMWolpinandWomensenterghRNBSghRNBSenPhDUCSFHelenDillerFamilyComprehensiveCancerCenterAmolK.Narang,MD§TheSidneyKimmelComprehensiveosticgyosticgy¤Gastroenterology‡Hematology/Hematologyoncology†Medicaloncology≠Pathology¥Patientadvocacy§Radiotherapy/Radiationoncology¶Surgery/Surgicaloncology*Discussionsectionwritingcommittee**Development/writingsubcommittee**JorgeObando,MD¤stituteVersion1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.AmpullaryAdenocarcinomaPanelMembersofAmpullaryNeoplasmAMPyAdenomaAMPAdenocarcinoma(AMP-3)LocalizedDisease(AMP-4)PostoperativeAdjuvantTherapy(AMP-5)seaseAmpullaryAdenocarcinomaPanelMembersofAmpullaryNeoplasmAMPyAdenomaAMPAdenocarcinoma(AMP-3)LocalizedDisease(AMP-4)PostoperativeAdjuvantTherapy(AMP-5)seaseAMPssionAMPPrinciplesofDiagnosis,Imaging,andStaging(AMP-A)PancreaticCancerRadiologyReportingTemplate(AMP-A,5of8)PrinciplesofStentManagement(AMP-B)PrinciplesofSurgicalTechnique(AMP-C)PathologicAnalysis:SpecimenOrientation,HistologicSections,andReporting(AMP-D)PrinciplesofSystemicTherapy(AMP-E)PrinciplesofRadiationTherapy(AMP-F)PrinciplesofPalliationandSupportiveCare(AMP-G)ocarcinomadexdNCCNCategoriesofPreference:Allrecommendationsareconsideredappropriate.SeeNCCNCategoriesofPreference.TheNCCNGuidelinesareastatementofevidenceandconsensusoftheauthorsregardingtheirviewsofcurrentlyacceptedapproachestotreatmentAnyclinicianseekingtoapplyorconsulttheNCCNGuidelinesisexpectedtouseindependentmedicaljudgmentinthecontextofindividualstancestodetermineanypatientscareortreatmentTheNationalComprehensiveCancerNetworkNCCNmakesnorepresentationsorwarrantiesofanykindregardingtheircontentuseorapplicationanddisclaimsanyresponsibilityfortheirapplicationoruseinanywayTheNCCNbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.©2022.Version1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadexCLINICALWORKUPTREATMENTPRESENTATIONcionymprotocolCTandpelvisandpelvisa•Esophagogastroduodenoscopy(EGD)±endoscopicultrasound(EUS)withbiopsy•ColonoscopyifnotpreviouslyperformedaccordingtoestablishedguidelinesHigh-gradedysplasiaSeeAmpullaryAdenoma(AMP-2)denocarcinomaAdenocarcinoma(AMP-3)aSeePrinciplesofDiagnosis,Imaging,andStaging(AMP-A).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.AMP-1PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadexCLINICALPRESENTATIONTREATMENTmpullaryNegativemarginsampullectomyampullectomybNegativemargins Pancreatoduodenectomy PancreatoduodenectomybtomybampullectomyampullectomybNegativemarginssrPancreatoduodenectomybtomybEndoscopicsurveillanceillanceEndoscopicsurveillanceillancebSeePrinciplesofSurgicalTechnique(AMP-C).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.AMP-2rfunctionstbaselineACEA•ConsiderERCP/PTCasclinicallyindicated•Considerestingforinheritedmutationsc•MultidisciplinaryondPrintedbyMinTangon3/14/20227:27:24AM.ForpersonalrfunctionstbaselineACEA•ConsiderERCP/PTCasclinicallyindicated•Considerestingforinheritedmutationsc•MultidisciplinaryondocarcinomadexCLINICALPRESENTATIONAdenocarcinomaWORKUP•CTchest,andpancreasprotocolCTofMetastaticTREATMENT•ConsiderMRIforindeterminateliverlesionsasclinicallyindicated•HistologicsubtypepancreatobiliaryversusintestinalifpossibletepreferredeonsidermoleculartepreferredeonsidermolecularprofilingfoftumortissueasallyindicatedaSeePrinciplesofDiagnosis,Imaging,andStaging(AMP-A).cGenetictestingforinheritedmutationsisrecommendedforanypatientwithconfirmedampullarycancer,usingcomprehensivegenepanelsforhereditarycancersyndromes.Geneticcounselingisrecommendedforpatientswhotestpositiveforapathogenicmutation(ATM,BRCA1,BRCA2,CDKN2A,MLH1,MSH2,MSH6,PALB2,PMS2,STK11,andTP53)orforpatientswithapositivefamilyhistoryofcancer,especiallypancreatic/ampullarycancer,regardlessofmutationstatus.SeeNCCNGuidelinesforGenetic/FamilialHighRiskAssessment:Breast,Ovarian,andPancreatic.dMultidisciplinaryreviewshouldconsiderinvolvingexpertisefromdiagnosticimaging,interventionalendoscopy,medicaloncology,radiationoncology,surgery,pathology,geriatricmedicine,geneticcounseling,andpalliativecare(seePrinciplesofPalliationandSupportiveCare[AMP-G]).Considerconsultationwitharegistereddietitian.SeeNCCNGuidelinesforOlderAdultOncologyandNCCNGuidelinesforPalliativeCare.eCorebiopsyisrecommended,ifpossible,toobtainadequatetissueforpossibleancillarystudies.fTumor/somaticmolecularprofilingisrecommendedforpatientswithlocallyadvanced/metastaticdiseasewhoarecandidatesforanti-cancertherapytoidentifyuncommonmutations.Considerspecificallytestingforpotentiallyactionablesomaticfindingsincluding,butnotlimitedto:fusions(ALK,NRG1,NTRK,ROS1,FGFR2,RET),mutations(BRAF,BRCA1/2,KRAS,PALB2),amplifications(HER2),microsatelliteinstability(MSI)and/ormismatchrepair(MMR)deficiency.Testingontumortissueispreferred;however,cell-freeDNAtestingcanbeconsiderediftumortissuetestingisnotfeasible.SeeDiscussion.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-3Version1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.icularlyinighriskpatientsiPrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.icularlyinighriskpatientsiocarcinomadexCLINICALPRESENTATIONTREATMENTProceedtosurgerywithoutneoadjuvanttherapy)SurgerygProceedtosurgerywithoutroradiationhjoradiationhjkstentlifstentlifclinicallyTorMRIResectableSurgerygUnresectablePeMetastaticDiseaseAMPgSeePrinciplesofSurgicalTechnique(AMP-C)andPathologicAnalysis:SpecimenOrientation,HistologicSections,andReporting(AMP-D).hSeePrinciplesofSystemicTherapy(AMP-E).iHigh-riskfeaturesincludeimagingfindings,markedlyelevatedCA19-9,markedlyelevatedcarcinoembryonicantigen(CEA),largeprimarytumors,largeregionallymphnodes,excessiveweightloss,andextremepain.jThereislimitedevidencetorecommendspecificneoadjuvantregimensoff-study,andpracticesvarywithregardtotheuseofchemotherapyandchemoradiation.kSeePrinciplesofRadiationTherapy(AMP-F).lSeePrinciplesofStentManagement(AMP-B).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-4Version1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.kSeePrinciplesofRadiationTherapy(AMP-F).mInitiationofadjuvantsystemictherapyisrecommendedwithin12weeksofsurgeryifthepatientismedicallyfit.TheoptimaldurationoftreatmentiskSeePrinciplesofRadiationTherapy(AMP-F).mInitiationofadjuvantsystemictherapyisrecommendedwithin12weeksofsurgeryifthepatientismedicallyfit.Theoptimaldurationoftreatmentis4to6months.ocarcinomadexPOSTOPERATIVEADJUVANTTREATMENTTREATMENTSURVEILLANCEyobservationSystemictherapyh,m±StageIobservationSystemictherapyh,m±observationStageIIchemoradiationh,k,mobservationStageIIIStageIIISystemictherapyh,m±StageIVSeeMetastaticDisease(AMP-6)Surveillanceevery3-6monthsfor2years,thenevery6-12monthsion•Historyandphysicalexamination(H&P)•ChestCTandCTorMRIoftrastaabdomenandpelvistrastahSeePrinciplesofSystemicTherapy(AMP-E).aSeePrinciplesofhSeePrinciplesofSystemicTherapy(AMP-E).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-5Version1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadexMETASTATICDISEASETREATMENTtictestingforinheritedmutations,ifnotlecularproilingoftumortissue,ifnotGoodPSnPoorPStionhktionhkcctherapyhllowedllowedbyrpalliativeSystemicSystemictherapyhfollowedbylocal-directedtherapytoliverorlungtastasesforselectpatientswithligometastaticdiseaseandresponsetablediseasetosystemictherapyprogressionSeeAMP-7PalliativeandbestsupportivecareoystemictherapyhTargetedtherapyhbasedonmolecularproilingfasclinicallyindicatedliativeliativeRTkdGenetictestingforinheritedmutationsisrecommendedforanypatientwithconfirmedampullarycancer,usingcomprehensivegenepanelsforhereditarycancersyndromes.Geneticcounselingisrecommendedforpatientswhotestpositiveforapathogenicmutation(ATM,BRCA1,BRCA2,CDKN2A,MLH1,MSH2,MSH6,PALB2,PMS2,STK11,andTP53)orforpatientswithapositivefamilyhistoryofcancer,especiallypancreatic/ampullarycancer,regardlessofmutationstatus.SeeNCCNGuidelinesforGenetic/FamilialHighRiskAssessment:Breast,Ovarian,andPancreatic.fTumor/somaticmolecularprofilingisrecommendedforpatientswithlocallyadvanced/metastaticdiseasewhoarecandidatesforanti-cancertherapytoidentifyuncommonmutations.Considerspecificallytestingforpotentiallyactionablesomaticfindingsincluding,butnotlimitedto:fusions(ALK,NRG1,NTRK,ROS1,FGFR2,RET),mutations(BRAF,BRCA1/2,KRAS,PALB2),amplifications(HER2),microsatelliteinstability(MSI)and/ormismatchrepair(MMR)deficiency.Testingontumortissueispreferred;however,cell-freeDNAtestingcanbeconsiderediftumortissuetestingisnotfeasible.SeeDiscussion.hSeePrinciplesofSystemicTherapy(AMP-E).kSeePrinciplesofRadiationTherapy(AMP-F).nDefinedasECOG0–1,withgoodbiliarydrainageandadequatenutritionalintake.oSeePrinciplesofPalliationandSupportiveCare(AMP-G).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-6Version1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadexDISEASEPROGRESSIONSUBSEQUENTTHERAPYpmolecularproiling,fasclinicallymolecularproiling,fasclinicallyindicatedSystemicSystemictherapyhorpossiblytargetedtherapyf,hbasedonPalliativeRTkforseverepainrefractorytoanalgesictherapyPalliativerialPalliativeandbestsupportivecareoystemictherapyhTargetedtherapyf,hbasedonmolecularproiling,fasclinicallyindicatediativeiativeRTkfTumorsomaticmolecularprofilingisrecommendedforpatientswithlocallyadvancedmetastaticdiseasewhoarecandidatesforanti-cancertherapytoidentifyuncommonmutationsConsiderspecificallytestingforpotentiallyactionablesomaticfindingsincludingbutnotlimitedto:fusions(ALK,NRG1,onsBRAFBRCAKRASPALBamplifications(HER2),microsatelliteinstability(MSI)and/ormismatchrepairrredhowevercellfreeDNAtestingcanbeconsiderediftumortissuetestingisnotfeasible.SeeDiscussion.hSeePrinciplesofSystemicTherapy(AMP-E).kSeePrinciplesofRadiationTherapy(AMP-F).nDefinedasECOG0–1,withgoodbiliarydrainageandadequatenutritionalintake.oSeePrinciplesofPalliationandSupportiveCare(AMP-G).pSerialimagingasindicatedtoassessdiseaseresponse.SeePrinciplesofDiagnosis,Imaging,andStaging(AMP-A).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-7Version1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.AMP-AOF8institutionalpreferencesMultiplanarreconstructionispreferredasitallowsprecisevisualizationoftherelationshipoftheprimarytumorPrintedbyMinTangon3/14/20227:27:24AM.ForAMP-AOF8institutionalpreferencesMultiplanarreconstructionispreferredasitallowsprecisevisualizationoftherelationshipoftheprimarytumorocarcinomadexPRINCIPLESOFDIAGNOSIS,IMAGING,ANDSTAGINGDecisionsaboutdiagnosticmanagementandresectabilityshouldinvolvemultidisciplinaryconsultationatahigh-volumecenterwithreferencetoappropriatehighqualityimagingstudiestoevaluatetheextentofdiseaseResectionsshouldbedoneatinstitutionsthatperformalargenumberatleastofpancreaticresectionsand/orendoscopicandsurgicalampullectomyannually.Highqualitydedicatedimagingoftheampullaryregionshouldbeperformedatpresentation(evenifstandardCTimagingisalreadyavailablepreferablywithinweeksofsurgeryandfollowingneoadjuvanttreatmenttoprovideadequatestagingandassessmentofresectabilitystatus.Imagingshouldbedonepriortostenting,whenpossible.•ImagingshouldincludededicatedpancreaticCTofabdomen(preferred)orMRIwithcontrast.pMultidetectorcomputedtomography(MDCT)angiography,performedbyacquiringthin,preferablysub-millimeter,axialsectionsusingaimagingtoolfordedicatedpancreaticimaging.aScancoveragecanbeextendedtocoverthechestandpelvisforcompletestagingasimagingtoolfordedicatedpancreaticimaging.aScancoveragecanbeextendedtocoverthechestandpelvisforcompletestagingaspertothemesentericvasculatureaswellasdetectionofsubcentimetermetastaticdeposits.SeeMDCTPancreaticAdenocarcinomaProtocol,PANC-A(3of8).pMRIismostcommonlyusedasaproblem-solvingtool,particularlyforcharacterizationofCT-indeterminateliverlesionsorwhencontrast-enhancedCTcannotbeobtained(asincaseswithsevereallergytoiodinatedintravenouscontrastmaterial).ThispreferenceforusingMDCTasthemainimagingtoolinmanyhospitalsandimagingcentersismainlyduetothehighercostandlackofwidespreadavailabilityofMRIcomparedtoCT.SeeMRIPancreaticAdenocarcinomaProtocol,AMP-A(4of8).•Thedecisionregardingresectabilitystatusshouldbemadebyconsensusatmultidisciplinarymeetings/discussionsfollowingthecompleteassessmentandreportingofallimagingcriteriaessentialforoptimalstaging,whichwillimprovethedecision-makingprocess.aacquisitionofcompleteassessmentandreportingofallimagingcriteriaessentialforoptimalstaging,whichwillimprovethedecision-makingprocess.aSeePancreaticCancerRadiologyReportingTemplateAMPAofThistemplatecanalsobeusedforampullarytumors.ancisIRChariSTetalPancreaticductaladenocarcinomaradiologyreportingtemplateconsensusstatementoftheSocietyofAbdominalRadiologyandtheAmericanPancreaticAssociationRadiology260.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2022,03/09/22©2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRights
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 客户分级评定标准及主要评定方法第一部分客户分级评定标准的构成
- 经济全球化与经济国际化的区别与联系
- 广西钦州市第四中学2024-2025学年高一物理上学期第十一周测试题12月
- 2024年中国游戏产业AIGC市场前景及投资研究报告
- 人教版一年级上册数学全册教案
- 数学苏教版一年级数学上册第五单元教学进度计划及教案
- 乙炔气主管吹扫方案9-18
- 路基施工测量方案
- 《新编简明英语语言学教程》1-6章复习题集
- 公司、项目部、各个班组安全培训试题带答案(培优)
- 部编版八年级语文上课件第三单元课外古诗词诵读(《庭中有奇树》《龟虽寿》《赠从弟(其二)》《梁甫行》)
- 岳阳楼记 全国一等奖
- 2023年保险行业抖音运营推广策划方案
- 思想道德与法治2023版教学设计第六章 学习法治思想 提升法治素养
- 园林工程施工技术指导规范
- 学生宿舍管理系统测试计划书
- 新型氧疗-经鼻高流量吸氧
- 2023年网络安全知识竞赛题库及答案(共290题)
- 安全生产责任制考核记录
- 代际领导力-用90后思维管理90后-完整版
- ttester eng112k翻译晶体管测试仪带AVR微控制器和
评论
0/150
提交评论